EFFORT Protein trial: questions remain

Affiliations

Comment

G Jan Zijlstra. Lancet. 2023.

. 2023 Sep 16;402(10406):963.

doi: 10.1016/S0140-6736(23)01254-0.

¹ Department of Intensive Care Medicine, Amsterdam University Medical Centers, Amsterdam 1081, Netherlands. Electronic address: g.j.zijlstra@amsterdamumc.nl.

Erratum in

Department of Error.
[No authors listed] [No authors listed] Lancet. 2023 Oct 14;402(10410):1328. doi: 10.1016/S0140-6736(23)02237-7. Lancet. 2023. PMID: 37838439 No abstract available.

No abstract available

EFFORT Protein trial: questions remain - Authors' reply.
Patel JJ, Lee ZY, Stoppe C, Heyland DK. Patel JJ, et al. Lancet. 2023 Sep 16;402(10406):964. doi: 10.1016/S0140-6736(23)01253-9. Lancet. 2023. PMID: 37716768 No abstract available.

The effect of higher protein dosing in critically ill patients with high nutritional risk (EFFORT Protein): an international, multicentre, pragmatic, registry-based randomised trial.
Heyland DK, Patel J, Compher C, Rice TW, Bear DE, Lee ZY, González VC, O'Reilly K, Regala R, Wedemire C, Ibarra-Estrada M, Stoppe C, Ortiz-Reyes L, Jiang X, Day AG; EFFORT Protein Trial team. Heyland DK, et al. Lancet. 2023 Feb 18;401(10376):568-576. doi: 10.1016/S0140-6736(22)02469-2. Epub 2023 Jan 25. Lancet. 2023. PMID: 36708732 Clinical Trial.